Companion Diagnostics Market by Product Type (Immunohistochemistry, In Situ Hybridization, Next Generation Sequencing), Application (Genetic Disorders, Infectious Diseases, Oncology), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Companion Diagnostics Market was valued at USD 3.49 billion in 2024 and is projected to grow to USD 3.79 billion in 2025, with a CAGR of 9.01%, reaching USD 6.96 billion by 2032.
A concise strategic orientation that outlines how companion diagnostics integrate technological, clinical, and commercial priorities to reshape precision medicine landscapes
Companion diagnostics occupy a pivotal position at the intersection of laboratory science, clinical care, and commercial strategy. Rapid advances in molecular biology and laboratory instrumentation have sharpened the ability to match therapies to specific biological profiles, and as a result, companion diagnostics now function as critical enablers of personalized treatment pathways. This introduction outlines the core drivers shaping the field, the types of stakeholders who rely on these assays, and the ways in which technological innovation and regulatory evolution are reshaping expectations for clinical evidence and operational execution.
Across research institutions, diagnostic laboratories, hospitals, and biopharmaceutical organizations, companion diagnostics are no longer auxiliary tools but essential components of product development and clinical decision-making. Investors and commercial teams increasingly view diagnostic partnerships as strategic levers that influence trial design, labeling outcomes, and post-market access. Consequently, organizational strategies must integrate diagnostic considerations from discovery through commercialization. This introduction frames the subsequent sections by emphasizing how convergence between molecular platforms, data analytics, and clinical workflows creates new opportunities while raising complex operational, regulatory, and reimbursement challenges that stakeholders must navigate effectively.
How advances in molecular platforms, digital diagnostics, and evolving regulatory and reimbursement paradigms are reshaping companion diagnostics development and commercialization
The companion diagnostics landscape is undergoing transformative shifts driven by advances in sequencing, digital pathology, and data-centric clinical workflows. Innovations in next generation sequencing and high-sensitivity PCR methods have expanded the range of detectable biomarkers and reduced time-to-result, enabling more complex companion diagnostic strategies to be embedded into both clinical trials and routine care. At the same time, digital pathology and image analysis tools are altering how tissue-based assays are standardized and interpreted, creating pathways for automation and remote review that improve reproducibility and scalability.
Meanwhile, the regulatory and payer environments are evolving toward evidence frameworks that emphasize clinical utility, real-world performance, and value-based reimbursement. Regulators are seeking clearer links between biomarker status and therapeutic benefit, and payers are increasingly asking for outcomes data that demonstrate improved patient pathways and cost offsets. These expectations elevate the importance of robust prospective and retrospective data collection and create impetus for integrated diagnostic-therapeutic development plans. In parallel, commercial strategies are shifting to form closer collaborations between diagnostic developers, pharmaceutical sponsors, and healthcare providers, with shared risk and data-sharing agreements becoming more common. Collectively, these forces are accelerating a transition from single-analyte assays to multiplexed and comprehensive panels informed by advanced analytics, creating new competitive dynamics and partnership models for organizations that can align technological capability with clinical and commercial imperatives.
Assessment of cumulative tariff-driven disruptions to companion diagnostics supply chains, procurement strategies, and competitive dynamics through 2025
The imposition and expansion of tariffs in 2025 have introduced cumulative pressures that affect procurement strategies, supply chains, and cost structures for manufacturers and end users of companion diagnostics. Tariffs that target imported laboratory instruments, reagents, or componentry create direct cost implications that cascade through distributors, hospitals, and diagnostic laboratories. In response, many stakeholders are reassessing supplier portfolios, increasing inventory buffers, and accelerating qualification of alternative vendors to mitigate exposure to single-source dependencies.
Beyond direct cost impacts, tariffs amplify strategic emphasis on regional sourcing, manufacturing footprint optimization, and nearshoring. Diagnostic firms that control manufacturing or have diversified regional production capabilities gain resilience in pricing and delivery timelines. Conversely, companies heavily reliant on cross-border suppliers face both increased landed costs and administrative friction associated with customs compliance. These dynamics prompt procurement leaders to negotiate longer-term contracts, adopt hedging strategies for critical reagents, and explore contract manufacturing partnerships to stabilize supply. Importantly, tariffs also influence innovation timelines; incremental cost increases can shift prioritization away from lower-margin reagent kits toward higher-value, integrated platform solutions where margin can absorb cost volatility. The cumulative impact is a reshaped competitive landscape where supply chain agility, manufacturing flexibility, and commercial contracting sophistication become critical differentiators.
Segment-focused analysis revealing how product platform complexity, clinical application needs, end-user workflows, and channel strategies shape companion diagnostics adoption
Segment-level perspectives reveal differentiated value drivers and operational requirements across product types, applications, end users, and distribution channels. Product complexity ranges from tissue-based assays such as immunohistochemistry and in situ hybridization to molecular techniques that include next generation sequencing and polymerase chain reaction platforms. Within next generation sequencing, targeted sequencing, transcriptome sequencing, and whole genome sequencing each carry unique sample preparation, bioinformatics, and validation demands, while polymerase chain reaction modalities such as digital PCR and quantitative PCR require different sensitivity and throughput considerations that influence kit design, instrumentation, and laboratory workflows.
Application areas shape clinical utility and evidence generation pathways. Oncology continues to be a primary use case where companion diagnostics directly inform therapeutic selection and trial enrichment, whereas genetic disorders, infectious diseases, and pharmacogenomics each impose distinct clinical and regulatory expectations related to analytic validity and clinical relevance. These differences drive variation in study design and post-market data collection obligations. End-user requirements further modulate product design and service models; academic and research institutes prioritize flexibility and high-content data, diagnostic laboratories emphasize throughput, standardization, and workflow efficiency, hospitals require integration with clinical information systems and rapid turnaround, and pharmaceutical companies focus on regulatory alignment and trial readiness.
Distribution channels dictate reach and customer experience. Direct tender processes often favor validated, large-scale implementations and structured service agreements, distributor sales enable broader geographic coverage and smaller account access, and online sales support lower-touch procurement for standardized kits and consumables. Taken together, these segmentation lenses indicate that successful strategies will be those that align product architecture, evidence generation, and commercial models to the specific expectations of application areas, end users, and preferred distribution pathways, thereby maximizing adoption across diverse clinical and research settings.
Regional perspectives on regulatory frameworks, adoption maturity, and manufacturing strategies that determine companion diagnostics market trajectories across major global territories
Geographic perspectives highlight differing market maturation, regulatory regimes, reimbursement practices, and supply chain dynamics across major regions. The Americas exhibit advanced adoption of precision oncology diagnostics and a well-established ecosystem of clinical laboratories and biopharmaceutical partners, resulting in high demand for comprehensive molecular assays and integrated reporting solutions. Meanwhile, Europe, Middle East & Africa present a complex mosaic of regulatory pathways and reimbursement systems where harmonization efforts and cross-border clinical collaborations coexist with national-level procurement practices, driving demand for adaptable assay platforms and robust clinical utility evidence.
Asia-Pacific is characterized by rapid capacity building, significant investments in domestic manufacturing, and diverse healthcare infrastructure, which together create opportunities for scalable, cost-efficient diagnostic solutions and regional R&D partnerships. Across all regions, local regulatory expectations and procurement behaviors influence commercialization roadmaps, and regional manufacturing or distribution strategies can materially affect pricing and availability. Consequently, companies that tailor regulatory submissions, evidence strategies, and channel approaches to regional nuances while maintaining global quality and interoperability standards will be better positioned to capture demand and navigate cross-border operational challenges.
Competitive landscape analysis highlighting how platform performance, assay validation, and integrated service models define strategic differentiation and partnership opportunities
A review of competitive dynamics indicates a stratified landscape where platform providers, assay developers, and integrated service organizations each occupy distinct strategic positions. Platform providers that offer scalable sequencing and PCR instruments compete on throughput, sample-to-answer time, and data management capabilities, which influence laboratory adoption and partnership opportunities. Assay developers focus on biomarker validation, clinical-grade kit development, and regulatory clearance strategies, often collaborating with therapeutic sponsors to align diagnostic claims with drug labels. Integrated service organizations combine laboratory operations with data analytics and clinical support services to provide end-to-end solutions for sites that prefer outsourcing rather than in-house development.
Strategic differentiation increasingly hinges on the ability to demonstrate analytic robustness, streamline laboratory workflows, and deliver actionable clinical insights. Partnerships and licensing agreements between diagnostic companies and pharmaceutical sponsors continue to be a primary route to market for companion diagnostics tied to specific therapies, while alliances with hospital networks and reference laboratories support broader clinical deployment. Additionally, investments in software, cloud-based reporting, and quality management systems are becoming as important as wet-lab capabilities, because clinicians and payers demand clear, interpretable outputs that integrate with electronic health records and support decision-making at the point of care.
Practical strategic recommendations for diagnostic developers and stakeholders to align innovation, evidence generation, and supply chain resilience for sustainable growth
Industry leaders should prioritize a pragmatic combination of technological investment, evidence generation, and supply chain resilience to capture long-term value. First, aligning product development with clinical utility endpoints will ensure diagnostic claims resonate with clinicians and payers, and designing validation studies that produce real-world evidence will accelerate reimbursement conversations. Second, investing in modular, interoperable platforms that support multiple assay chemistries and data outputs reduces customer switching costs and enhances cross-selling opportunities across research and clinical segments.
Simultaneously, organizations must strengthen supply chain and procurement strategies to mitigate tariff exposure and component shortages by diversifying suppliers, qualifying secondary manufacturers, and exploring regional production partnerships. Commercially, tailored go-to-market approaches that reflect the needs of hospitals, diagnostic laboratories, research institutions, and pharmaceutical sponsors will yield higher adoption rates than one-size-fits-all models. Finally, embracing digital workflows for result reporting, quality control, and clinician engagement will improve usability and facilitate integration into care pathways. Taken together, these actions position industry leaders to balance innovation with operational discipline and to convert scientific advances into sustainable clinical and commercial outcomes.
Transparent description of the mixed-methods research approach that combined literature synthesis, stakeholder engagement, and technical validation to generate robust companion diagnostics insights
The research methodology underpinning these insights combined systematic literature review, stakeholder interviews, and cross-validation of technical and regulatory information from primary and secondary sources. Literature and regulatory documents were synthesized to establish the baseline of clinical and technical expectations, while interviews with laboratory directors, diagnostic developers, payers, and clinical investigators provided contextual perspective on operational constraints, adoption drivers, and evidence needs. Technical assessments examined platform characteristics such as analytic sensitivity, throughput, and informatics capabilities to map the implications for laboratory workflows and clinical interpretation.
Data integrity was maintained through triangulation across multiple inputs and critical appraisal of source credibility. Limitations include the variability of national regulatory practices and the evolving nature of tariff policies, which may lead to rapid changes in operational conditions. To mitigate these uncertainties, scenario analysis and sensitivity checks were applied to qualitative findings, and recommendations were calibrated to emphasize adaptable strategies that maintain relevance despite regulatory or commercial shifts.
Concluding synthesis emphasizing the imperative to integrate technological innovation, robust evidence generation, and supply chain adaptability to realize the promise of companion diagnostics
In summary, the companion diagnostics arena is moving from discrete, single-test use cases toward integrated, multiplexed solutions that require coordinated evidence, regulatory, and commercial strategies. Technological advances in sequencing and PCR, combined with digital pathology and analytics, are expanding diagnostic capabilities and enabling more precise therapeutic alignment. At the same time, evolving regulatory expectations and payer demands underscore the need for rigorous clinical evidence and real-world outcome data to support adoption and reimbursement.
Operationally, tariff-driven pressures and supply chain dynamics emphasize the importance of manufacturing flexibility and procurement diversification. Region-specific regulatory and market characteristics demand tailored commercialization and regulatory strategies. For executives and technical leaders, the central priority is to align product development with clinical utility, invest in interoperable platforms and data services, and embed supply chain resilience into growth plans. These integrated actions will enable organizations to convert scientific promise into durable clinical impact and sustainable commercial performance.
Please Note: PDF & Excel + Online Access - 1 Year
A concise strategic orientation that outlines how companion diagnostics integrate technological, clinical, and commercial priorities to reshape precision medicine landscapes
Companion diagnostics occupy a pivotal position at the intersection of laboratory science, clinical care, and commercial strategy. Rapid advances in molecular biology and laboratory instrumentation have sharpened the ability to match therapies to specific biological profiles, and as a result, companion diagnostics now function as critical enablers of personalized treatment pathways. This introduction outlines the core drivers shaping the field, the types of stakeholders who rely on these assays, and the ways in which technological innovation and regulatory evolution are reshaping expectations for clinical evidence and operational execution.
Across research institutions, diagnostic laboratories, hospitals, and biopharmaceutical organizations, companion diagnostics are no longer auxiliary tools but essential components of product development and clinical decision-making. Investors and commercial teams increasingly view diagnostic partnerships as strategic levers that influence trial design, labeling outcomes, and post-market access. Consequently, organizational strategies must integrate diagnostic considerations from discovery through commercialization. This introduction frames the subsequent sections by emphasizing how convergence between molecular platforms, data analytics, and clinical workflows creates new opportunities while raising complex operational, regulatory, and reimbursement challenges that stakeholders must navigate effectively.
How advances in molecular platforms, digital diagnostics, and evolving regulatory and reimbursement paradigms are reshaping companion diagnostics development and commercialization
The companion diagnostics landscape is undergoing transformative shifts driven by advances in sequencing, digital pathology, and data-centric clinical workflows. Innovations in next generation sequencing and high-sensitivity PCR methods have expanded the range of detectable biomarkers and reduced time-to-result, enabling more complex companion diagnostic strategies to be embedded into both clinical trials and routine care. At the same time, digital pathology and image analysis tools are altering how tissue-based assays are standardized and interpreted, creating pathways for automation and remote review that improve reproducibility and scalability.
Meanwhile, the regulatory and payer environments are evolving toward evidence frameworks that emphasize clinical utility, real-world performance, and value-based reimbursement. Regulators are seeking clearer links between biomarker status and therapeutic benefit, and payers are increasingly asking for outcomes data that demonstrate improved patient pathways and cost offsets. These expectations elevate the importance of robust prospective and retrospective data collection and create impetus for integrated diagnostic-therapeutic development plans. In parallel, commercial strategies are shifting to form closer collaborations between diagnostic developers, pharmaceutical sponsors, and healthcare providers, with shared risk and data-sharing agreements becoming more common. Collectively, these forces are accelerating a transition from single-analyte assays to multiplexed and comprehensive panels informed by advanced analytics, creating new competitive dynamics and partnership models for organizations that can align technological capability with clinical and commercial imperatives.
Assessment of cumulative tariff-driven disruptions to companion diagnostics supply chains, procurement strategies, and competitive dynamics through 2025
The imposition and expansion of tariffs in 2025 have introduced cumulative pressures that affect procurement strategies, supply chains, and cost structures for manufacturers and end users of companion diagnostics. Tariffs that target imported laboratory instruments, reagents, or componentry create direct cost implications that cascade through distributors, hospitals, and diagnostic laboratories. In response, many stakeholders are reassessing supplier portfolios, increasing inventory buffers, and accelerating qualification of alternative vendors to mitigate exposure to single-source dependencies.
Beyond direct cost impacts, tariffs amplify strategic emphasis on regional sourcing, manufacturing footprint optimization, and nearshoring. Diagnostic firms that control manufacturing or have diversified regional production capabilities gain resilience in pricing and delivery timelines. Conversely, companies heavily reliant on cross-border suppliers face both increased landed costs and administrative friction associated with customs compliance. These dynamics prompt procurement leaders to negotiate longer-term contracts, adopt hedging strategies for critical reagents, and explore contract manufacturing partnerships to stabilize supply. Importantly, tariffs also influence innovation timelines; incremental cost increases can shift prioritization away from lower-margin reagent kits toward higher-value, integrated platform solutions where margin can absorb cost volatility. The cumulative impact is a reshaped competitive landscape where supply chain agility, manufacturing flexibility, and commercial contracting sophistication become critical differentiators.
Segment-focused analysis revealing how product platform complexity, clinical application needs, end-user workflows, and channel strategies shape companion diagnostics adoption
Segment-level perspectives reveal differentiated value drivers and operational requirements across product types, applications, end users, and distribution channels. Product complexity ranges from tissue-based assays such as immunohistochemistry and in situ hybridization to molecular techniques that include next generation sequencing and polymerase chain reaction platforms. Within next generation sequencing, targeted sequencing, transcriptome sequencing, and whole genome sequencing each carry unique sample preparation, bioinformatics, and validation demands, while polymerase chain reaction modalities such as digital PCR and quantitative PCR require different sensitivity and throughput considerations that influence kit design, instrumentation, and laboratory workflows.
Application areas shape clinical utility and evidence generation pathways. Oncology continues to be a primary use case where companion diagnostics directly inform therapeutic selection and trial enrichment, whereas genetic disorders, infectious diseases, and pharmacogenomics each impose distinct clinical and regulatory expectations related to analytic validity and clinical relevance. These differences drive variation in study design and post-market data collection obligations. End-user requirements further modulate product design and service models; academic and research institutes prioritize flexibility and high-content data, diagnostic laboratories emphasize throughput, standardization, and workflow efficiency, hospitals require integration with clinical information systems and rapid turnaround, and pharmaceutical companies focus on regulatory alignment and trial readiness.
Distribution channels dictate reach and customer experience. Direct tender processes often favor validated, large-scale implementations and structured service agreements, distributor sales enable broader geographic coverage and smaller account access, and online sales support lower-touch procurement for standardized kits and consumables. Taken together, these segmentation lenses indicate that successful strategies will be those that align product architecture, evidence generation, and commercial models to the specific expectations of application areas, end users, and preferred distribution pathways, thereby maximizing adoption across diverse clinical and research settings.
Regional perspectives on regulatory frameworks, adoption maturity, and manufacturing strategies that determine companion diagnostics market trajectories across major global territories
Geographic perspectives highlight differing market maturation, regulatory regimes, reimbursement practices, and supply chain dynamics across major regions. The Americas exhibit advanced adoption of precision oncology diagnostics and a well-established ecosystem of clinical laboratories and biopharmaceutical partners, resulting in high demand for comprehensive molecular assays and integrated reporting solutions. Meanwhile, Europe, Middle East & Africa present a complex mosaic of regulatory pathways and reimbursement systems where harmonization efforts and cross-border clinical collaborations coexist with national-level procurement practices, driving demand for adaptable assay platforms and robust clinical utility evidence.
Asia-Pacific is characterized by rapid capacity building, significant investments in domestic manufacturing, and diverse healthcare infrastructure, which together create opportunities for scalable, cost-efficient diagnostic solutions and regional R&D partnerships. Across all regions, local regulatory expectations and procurement behaviors influence commercialization roadmaps, and regional manufacturing or distribution strategies can materially affect pricing and availability. Consequently, companies that tailor regulatory submissions, evidence strategies, and channel approaches to regional nuances while maintaining global quality and interoperability standards will be better positioned to capture demand and navigate cross-border operational challenges.
Competitive landscape analysis highlighting how platform performance, assay validation, and integrated service models define strategic differentiation and partnership opportunities
A review of competitive dynamics indicates a stratified landscape where platform providers, assay developers, and integrated service organizations each occupy distinct strategic positions. Platform providers that offer scalable sequencing and PCR instruments compete on throughput, sample-to-answer time, and data management capabilities, which influence laboratory adoption and partnership opportunities. Assay developers focus on biomarker validation, clinical-grade kit development, and regulatory clearance strategies, often collaborating with therapeutic sponsors to align diagnostic claims with drug labels. Integrated service organizations combine laboratory operations with data analytics and clinical support services to provide end-to-end solutions for sites that prefer outsourcing rather than in-house development.
Strategic differentiation increasingly hinges on the ability to demonstrate analytic robustness, streamline laboratory workflows, and deliver actionable clinical insights. Partnerships and licensing agreements between diagnostic companies and pharmaceutical sponsors continue to be a primary route to market for companion diagnostics tied to specific therapies, while alliances with hospital networks and reference laboratories support broader clinical deployment. Additionally, investments in software, cloud-based reporting, and quality management systems are becoming as important as wet-lab capabilities, because clinicians and payers demand clear, interpretable outputs that integrate with electronic health records and support decision-making at the point of care.
Practical strategic recommendations for diagnostic developers and stakeholders to align innovation, evidence generation, and supply chain resilience for sustainable growth
Industry leaders should prioritize a pragmatic combination of technological investment, evidence generation, and supply chain resilience to capture long-term value. First, aligning product development with clinical utility endpoints will ensure diagnostic claims resonate with clinicians and payers, and designing validation studies that produce real-world evidence will accelerate reimbursement conversations. Second, investing in modular, interoperable platforms that support multiple assay chemistries and data outputs reduces customer switching costs and enhances cross-selling opportunities across research and clinical segments.
Simultaneously, organizations must strengthen supply chain and procurement strategies to mitigate tariff exposure and component shortages by diversifying suppliers, qualifying secondary manufacturers, and exploring regional production partnerships. Commercially, tailored go-to-market approaches that reflect the needs of hospitals, diagnostic laboratories, research institutions, and pharmaceutical sponsors will yield higher adoption rates than one-size-fits-all models. Finally, embracing digital workflows for result reporting, quality control, and clinician engagement will improve usability and facilitate integration into care pathways. Taken together, these actions position industry leaders to balance innovation with operational discipline and to convert scientific advances into sustainable clinical and commercial outcomes.
Transparent description of the mixed-methods research approach that combined literature synthesis, stakeholder engagement, and technical validation to generate robust companion diagnostics insights
The research methodology underpinning these insights combined systematic literature review, stakeholder interviews, and cross-validation of technical and regulatory information from primary and secondary sources. Literature and regulatory documents were synthesized to establish the baseline of clinical and technical expectations, while interviews with laboratory directors, diagnostic developers, payers, and clinical investigators provided contextual perspective on operational constraints, adoption drivers, and evidence needs. Technical assessments examined platform characteristics such as analytic sensitivity, throughput, and informatics capabilities to map the implications for laboratory workflows and clinical interpretation.
Data integrity was maintained through triangulation across multiple inputs and critical appraisal of source credibility. Limitations include the variability of national regulatory practices and the evolving nature of tariff policies, which may lead to rapid changes in operational conditions. To mitigate these uncertainties, scenario analysis and sensitivity checks were applied to qualitative findings, and recommendations were calibrated to emphasize adaptable strategies that maintain relevance despite regulatory or commercial shifts.
Concluding synthesis emphasizing the imperative to integrate technological innovation, robust evidence generation, and supply chain adaptability to realize the promise of companion diagnostics
In summary, the companion diagnostics arena is moving from discrete, single-test use cases toward integrated, multiplexed solutions that require coordinated evidence, regulatory, and commercial strategies. Technological advances in sequencing and PCR, combined with digital pathology and analytics, are expanding diagnostic capabilities and enabling more precise therapeutic alignment. At the same time, evolving regulatory expectations and payer demands underscore the need for rigorous clinical evidence and real-world outcome data to support adoption and reimbursement.
Operationally, tariff-driven pressures and supply chain dynamics emphasize the importance of manufacturing flexibility and procurement diversification. Region-specific regulatory and market characteristics demand tailored commercialization and regulatory strategies. For executives and technical leaders, the central priority is to align product development with clinical utility, invest in interoperable platforms and data services, and embed supply chain resilience into growth plans. These integrated actions will enable organizations to convert scientific promise into durable clinical impact and sustainable commercial performance.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
188 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of multiomic biomarkers into companion diagnostic assays for personalized therapies
- 5.2. Expansion of liquid biopsy based companion diagnostics for real-time treatment monitoring
- 5.3. Adoption of digital pathology and AI algorithms in companion diagnostic result interpretation
- 5.4. Collaboration between pharmaceutical and diagnostic developers for co-development of targeted therapies
- 5.5. Emergence of cost-effective point-of-care companion diagnostic platforms in emerging markets
- 5.6. Regulatory harmonization initiatives to streamline companion diagnostic approvals across major regions
- 5.7. Development of multiplex companion diagnostics enabling simultaneous profiling of multiple biomarkers
- 5.8. Growing investment in next-generation sequencing panels for comprehensive companion diagnostic testing
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Companion Diagnostics Market, by Product Type
- 8.1. Immunohistochemistry
- 8.2. In Situ Hybridization
- 8.3. Next Generation Sequencing
- 8.3.1. Targeted Sequencing
- 8.3.2. Transcriptome Sequencing
- 8.3.3. Whole Genome Sequencing
- 8.4. Polymerase Chain Reaction
- 8.4.1. Digital Pcr
- 8.4.2. Quantitative Pcr
- 9. Companion Diagnostics Market, by Application
- 9.1. Genetic Disorders
- 9.2. Infectious Diseases
- 9.3. Oncology
- 9.4. Pharmacogenomics
- 10. Companion Diagnostics Market, by End User
- 10.1. Academic And Research Institutes
- 10.2. Diagnostic Laboratories
- 10.3. Hospitals
- 10.4. Pharmaceutical Companies
- 11. Companion Diagnostics Market, by Distribution Channel
- 11.1. Direct Tender
- 11.2. Distributor Sales
- 11.3. Online Sales
- 12. Companion Diagnostics Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Companion Diagnostics Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Companion Diagnostics Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Abnova Corporation
- 15.3.3. Agendia, Inc.
- 15.3.4. Agilent Technologies, Inc.
- 15.3.5. Almac Group
- 15.3.6. Amoy Diagnostics Co., Ltd.
- 15.3.7. ARUP Laboratories
- 15.3.8. Bio-Techne Corporation
- 15.3.9. Biogenex Laboratories, Inc
- 15.3.10. bioMérieux SA
- 15.3.11. Danaher Corporation
- 15.3.12. Eli Lilly and Company
- 15.3.13. F. Hoffmann-La Roche AG
- 15.3.14. Guardant Health, Inc
- 15.3.15. ICON PLC
- 15.3.16. Illumina, Inc.
- 15.3.17. Invivoscribe Technologies, Inc.
- 15.3.18. Myriad Genetics, Inc.
- 15.3.19. NG biotech
- 15.3.20. QIAGEN N.V.
- 15.3.21. R-Biopharm AG
- 15.3.22. Siemens AG
- 15.3.23. Sysmex Corporation
- 15.3.24. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
